Humanigen Inc (HGENQ)

[cowtown jay]

I'm very glad to see this pre-print, dated yesterday, Jan 1, 2022.

The initial pre-print, dated May 5th, 2021, dealt with "LENZILUMAB EFFICACY AND SAFETY IN NEWLY HOSPITALIZED COVID-19 SUBJECTS." This is the material that has since been peer-reviewed and published in Lancet.

https://www.medrxiv.org/content/10.1101/2021.05.01.21256470v1.full

So I'll look forward to the peer-review regarding "EARLY LENZILUMAB TREATMENT OF COVID-19 PATIENTS USING C-REACTIVE PROTEIN AS A BIOMARKER IMPROVES EFFICACY." This is the material that Durrant has been presenting to the medical community, starting with the ICIS convention, and was likely discussed in the Type B meeting with the FDA, and with the MHRA last month.

I guess that we could hear from the MHRA at any time now, and from the FDA after their meeting minutes have been presented, perhaps in about two weeks.

Now that Q4 is over, I hope that we can also see a PR regarding how Europe is reacting to our effort with Clinigen.

The new pre-print really re-defines how effective lenz is as a therapeutic. No treatment is better. The need for an effective treatment has never been higher. Surely, our time has arrived.